tbuckley/cabot-search huggingface dataset:
SAT0410 Characteristics of abscesses during brucellar spondylodiscitis
Authors: O. Saidane, I. Oueslati, I. Mahmoud, A. Ben Tekaya, R. Tekaya, L. Abdelmoula
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Spondylodiscitis is a frequent and important complication of brucellosis. The occurrence of abscesses is common <h3>Objectives</h3> The aim of this study was to determine the characteristics of these collections and if there is an association between the diagnostic delay and their occurrence <h3>Methods</h3> we conducted a retrospective study of 27 patients admitted for Brucella spondylodyscitis over a period of 17 years [2000 and 2016]. Etiological diagnosis was made on a positive Wright agglutination test. All patients underwent a cross sectional imaging: spinal CT (13 cases) and/or spinal MRI (24 cases). <h3>Results</h3> twenty seven patients were included. Ten women and 17 men aged from 33 to 75 years. The most common symptoms were spinal pain (96,3%) and radiculalgia (44,4%). The most frequently involved segments were the lumbar spine (59.3%) and the dorsal spine (18.5%).Three patients (11,1%) suffered from cervical spondylodiscitis. The physical examination showed no paravertebral swelling or neurological abnormalities. Seventeen patients had abscesses on the cross sectional imaging (63%). Epidural fluid collections were revealed in 10 cases (37%). Nine patients had psoas abscesses (33,3%)with a bilateral involvement in 3 cases (11,1%). Less frequently, a prevertebral (18.5%), peri-vertebral(18.5%) and intradiscal collections (3.7%) were detected. A statistically significant positive association was found between a longer diagnosis delay and the presence of abscess on spinal MRI (p=0.036). <h3>Conclusions</h3> Epidural and paravertebral abscesses during Brucellar spondylodiscitis are frequent, especially if the diagnosis is delayed. However, they are rarely associated with neurological damage and must be sought consistently on the MRI <h3>Disclosure of Interest</h3> None declared
National Survey of Oncologists at National Cancer Institute–Designated Comprehensive Cancer Centers: Attitudes, Knowledge, and Practice Behaviors About LGBTQ Patients With Cancer
Authors: Matthew B. Schabath, Catherine A. Blackburn, Megan E. Sutter, Peter A. Kanetsky, Susan T. Vadaparampil, Vani N. Simmons, Julian A. Sanchez, Steven K. Sutton, Gwendolyn P. Quinn
Journal: Journal of Clinical Oncology (2019)

PURPOSE To identify potential gaps in attitudes, knowledge, and institutional practices toward lesbian, gay, bisexual, transgender, and queer/questioning (LGBTQ) patients, a national survey of oncologists at National Cancer Institute–Designated Comprehensive Cancer Centers was conducted to measure these attributes related to LGBTQ patients and desire for future training and education. METHODS A random sample of 450 oncologists from 45 cancer centers was selected from the American Medical Association’s Physician Masterfile to complete a survey measuring attitudes and knowledge about LGBTQ health and institutional practices. Results were quantified using descriptive and stratified analyses and by a novel attitude summary measure. RESULTS Of the 149 respondents, there was high agreement (65.8%) regarding the importance of knowing the gender identity of patients, which was contrasted by low agreement (39.6%) regarding the importance of knowing sexual orientation. There was high interest in receiving education regarding the unique health needs of LGBTQ patients (70.4%), and knowledge questions yielded high percentages of “neutral” and “do not know or prefer not to answer” responses. After completing the survey, there was a significant decrease ( P &lt; .001) in confidence in knowledge of health needs for LGB (53.1% agreed they were confident during survey assessment v 38.9% postsurvey) and transgender patients (36.9% v 19.5% postsurvey). Stratified analyses revealed some but limited influence on attitudes and knowledge by having LGBTQ friends and/or family members, political affiliation, oncology specialty, years since graduation, and respondents’ region of the country. CONCLUSION This was the first nationwide study, to our knowledge, of oncologists assessing attitudes, knowledge, and institutional practices of LGBTQ patients with cancer. Overall, there was limited knowledge about LGBTQ health and cancer needs but a high interest in receiving education regarding this community.
Abstract 16020: Narrowing Sex Differences in Lipoprotein Cholesterol Subclasses Following Menopause: Insights From the Very Large Database of Lipids (VLDL-10B)
Authors: Kristopher J Swiger, Seth S Martin, Michael J Blaha, Peter P Toth, Khurram Nasir, Gary Gerstenblith, Roger S Blumenthal, Steven R Jones
Journal: Circulation (2013)

Introduction: Women have a decreased risk of atherosclerotic cardiovascular disease relative to men up until mid-life, when the gap begins to close subsequent to menopause. However, sex differences throughout life in non-HDL-C, HDL-C, and lipoprotein subclasses are incompletely characterized. Hypothesis: We hypothesized that the lipid profile of women becomes less favorable compared to men after menopause. Methods: This Very Large Database of Lipids 10B (VLDL 10B) study examined 1,350,908 records of subjects clinically referred from 2009 to 2011 for advanced lipoprotein testing by ultracentrifugation (Atherotech, Birmingham, AL). By sex, we determined the median, 25th and 75th percentiles. Ratio variables were created for density subclasses of HDL-C, LDL-C, and VLDL-C. Results: Men show higher non-HDL-C than women for decades 3 to 5 (greatest difference in decade 4: 150 mg/dL in men vs 134 mg/dL in women); however, women consistently have greater median values after menopause (decade 9: 128 mg/dL in women...
Global Environmental Change and Noncommunicable Disease Risks
Authors: Howard Frumkin, Andy Haines
Journal: Annual Review of Public Health (2019)

Multiple global environmental changes (GECs) now under way, including climate change, biodiversity loss, freshwater depletion, tropical deforestation, overexploitation of fisheries, ocean acidification, and soil degradation, have substantial, but still imperfectly understood, implications for human health. Noncommunicable diseases (NCDs) make a major contribution to the global burden of disease. Many of the driving forces responsible for GEC also influence NCD risk through a range of mechanisms. This article provides an overview of pathways linking GEC and NCDs, focusing on five pathways: ( a) energy, air pollution, and climate change; ( b) urbanization; ( c) food, nutrition, and agriculture; ( d) the deposition of persistent chemicals in the environment; and ( e) biodiversity loss.
Reply to te Brake <i>et al.</i>: Conflicting Findings on an Intermediate Dose of Rifampicin for Pulmonary Tuberculosis
Authors: Gustavo E. Velásquez, Meredith B. Brooks, Julia M. Coit, Epifanio Sánchez Garavito, Roger I. Calderón, Judith Jiménez, Karen Tintaya, Charles A. Peloquin, Elna Osso, Leonid Lecca, Geraint R. Davies, Carole D. Mitnick
Journal: American Journal of Respiratory and Critical Care Medicine (2019)
Syncope
Authors: Georg Goliasch, Andreas A. Kammerlander, Christian Nitsche, Carolina Dona, Laurin Schachner, Begüm Öztürk, Christina Binder, Franz Duca, Stefan Aschauer, Günther Laufer, Christian Hengstenberg, Diana Bonderman, Julia Mascherbauer
Journal: JACC. Cardiovascular imaging (2018)
ACC/AATS/AHA/ASE/ASNC/HRS/SCAI/SCCT/SCMR/STS 2019 Appropriate Use Criteria for Multimodality Imaging in the Assessment of Cardiac Structure and Function in Nonvalvular Heart Disease
Authors: John U. Doherty, Smadar Kort, Roxana Mehran, Paul Schoenhagen, Prem Soman, Gregory J. Dehmer, John U. Doherty, Paul Schoenhagen, Thomas M. Bashore, Nicole M. Bhave, Dennis A. Calnon, Blase Carabello, John Conte, Timm Dickfeld, Daniel Edmundowicz, Victor A. Ferrari, Michael E. Hall, Brian Ghoshhajra, Praveen Mehrotra, Tasneem Z. Naqvi, T. Brett Reece, Randall C. Starling, Molly Szerlip, Wendy S. Tzou, John B. Wong
Journal: Journal of the American College of Cardiology (2019)
SAT0514 Mri – guided therapy for systemic sclerosis associated myositis
Authors: Y. Braun-Moscovici, D. Militianu, N. Puchkov, D. Markovits, M. Braun, M.A. Nahir, A. Balbir-Gurman
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Muscle involvement in systemic sclerosis (SSc) has a significant impact on morbidity, functional capacity, and mortality. The muscle histopathology is heterogeneous including inflammatory and fibrotic changes. Currently there are no satisfactory means to diagnose inflammatory myopathy in SSc pts with normal creatine kinase (CK) and to assess the response to therapy. <h3>Objectives</h3> Our aim was to evaluate whether muscle magnetic resonance imaging (MRI) might be a tool to diagnose inflammatory myopathy in SSc patients (pts) and to assess the effect of muscle oriented- immunomodulatory therapy. <h3>Methods</h3> We retrospectively analysed the clinical data of 290 consecutive SSc pts seen at our centre between the years 2012–2017. Our cohort is part of the EUSTAR registry (centre 042). Pts with muscle weakness as defined by the Medsger muscle severity score of ≥1 and at least one MRI study were included. Clinical data analyzis included SSc subtype, disease duration, modified Rodnan skin score (mRSS), Medsger muscle severity score, CK, autoantibody profile, MRI and immunomodulatory treatment. <h3>Results</h3> 26 pts with muscle weakness answered the criteria of Medsger muscle severity score of ≥1 MRI data were available, in 17 of the pts. Muscle oedema and fasciitis were seen in MRI in 13 pts (10 diffuse subset, median: age 40, disease duration 1.25 years, mRSS 13.5). MRI was normal in 4 pts (2diffuse SSc, median: age 50 years, disease duration 6 years, mRSS 4). CK was normal in 10 pts with pathologic MRI. Anti-topoisomerase was positive in 6 pts, RNA polymerase 3 – in 3 pts, anti-centromere – in 2 pts and 6 pts were only ANA positive. Muscle biopsy results were available in 4 pts: Biopsy was compatible with myositis in 3 pts with pathologic MRI and revealed fibrosis in 1 pt with normal MRI. 14 pts received immunomodulatory treatment: rituximab (3 pts), rituximab and intravenous immunoglobulins (IVIG) (3 pts), IVIG and methotrexate/azathioprine/mycophenolate mofetil.<sup>8</sup> A second MRI was performed in 6 pts with first pathologic MRI, after 12 months of treatment. Significant regression of muscle oedema and perifasciitis was observed in 5 pts and correlated with clinical amelioration, with improvement of muscle strength. No clinical and imaging improvement occurred in one patient, despite the treatment. No change in muscle strength was seen in the patient with normal MRI and evidence of fibrosis on muscle biopsy, although the skin score improved. <h3>Conclusions</h3> MRI might serve as a non-invasive tool for diagnosis of inflammatory myopathy in SSc pts with early disease, Medsger muscle severity score of ≥1 and normal CK and for assessment of treatment efficacy. <h3>Disclosure of Interest</h3> None declared
Subclonal Mutations of TP53 Are Common in Untreated Follicular Lymphoma and Mutation Status Is Predictive of PFS When CHOP Is Combined with 131-Iodine Tositumomab but Not with Rituximab: An Analysis of SWOG S0016
Authors: Richard Burack, Hongli Li, Janice M Spence, Diana Adlowitz, Lisa M. Rimsza, Rita M. Braziel, Catherine M. Spier, Mark S Kaminski, John P. Leonard, Richard I. Fisher, Michael L. Leblanc, Sonali M. Smith, Jonathan W. Friedberg
Journal: Blood (2018)
Abstract 14274: Characteristics and Natural History of Hospitalized Heart Failure Patients With Diabetes Mellitus: Preserved versus Reduced Ejection Fraction
Authors: Siu-Hin Wan, Joshua P Slusser, David O Hodge, Horng H Chen
Journal: Circulation (2015)

Introduction: Among those hospitalized with heart failure, diabetes (DM) is a common comorbid condition and the population characteristics and natural history of those with preserved EF (HFpEF) versus those with reduced EF (HFrEF) remain undefined. Hypothesis: To determine the epidemiologic profile and natural history among those hospitalized with acute heart failure (AHF) with DM and compare outcomes of those with reduced versus preserved EF. Methods: A retrospective chart analysis of adults hospitalized with primary ICD diagnosis of AHF from Olmsted County hospitalized from 2005 - 2008, with follow up until 2013. Demographic, clinical and lab data were collected. Results: Of 912 subjects hospitalized with AHF, 381 (42%) had DM. Among subjects with AHF and DM, those with HFrEF were similar in age to those with HFpEF (76.3±11.7 years vs 78.3±11.2 years, p=0.12), but were more likely to be male (58% vs 37%, p&lt;0.001). Those with DM and HFrEF compared to HFpEF had less hypertension (95% vs 99%, p=0.046), but more coronary artery disease (89% vs 75%, p&lt;0.001), prior myocardial infarction (65% vs 33%, p&lt;0.001), and higher BNP values (1155±906 pg/mL vs 676±568 pg/mL, p&lt;0.001). E/e’ ratio was similar in those with DM and HFrEF versus HFpEF (22.6±10.4 vs 21.7±10.9, p=0.49), suggesting both groups had increased filling pressures. There was no difference in mortality between the HFrEF and HFpEF groups up to 5 years in either the DM group (p=0.46) or the non-DM group (p=0.11). However, those hospitalized with AHF and DM demonstrated a higher rate in those with HFrEF versus HFpEF groups in all cause rehospitalization (p=0.019) and heart failure rehospitalization (p=0.008). This was different from the non-DM group, where there was no difference between HFrEF and HFpEF in all cause hospitalization (p=0.31) or heart failure rehospitalization (p=0.19). Conclusions: In patients hospitalized for AHF with DM, those with HFrEF had increased all cause and heart failure hospitalization as compared to HFpEF. In contrast, subjects without DM had no differences in rehospitalization between the HFrEF and HFpEF groups. Further studies are warranted to define pathophysiological mechanism for this observation.
Association of Sleep Duration and Quality With Subclinical Atherosclerosis
Authors: Fernando Domínguez, Valentín Fuster, Juan Miguel Fernández-Alvira, Leticia Fernández-Friera, Beatriz López-Melgar, Ruth Blanco-Rojo, Antonio Fernández-Ortiz, Pablo García-Pavía, Javier Sanz, José M. Mendiguren, Borja Ibañez, Héctor Bueno, Enrique Lara-Pezzi, José M. Ordovás
Journal: Journal of the American College of Cardiology (2019)
Measurable Residual Disease Assessment By qPCR in Peripheral Blood Is an Informative Tool for Disease Surveillance in Childhood Acute Myeloid Leukemia
Authors: Kristian Juul-Dam, Hans Beier Ommen, Charlotte Guldborg Nyvold, Christiane Walter, Helen Vålerhaugen, Veli Kairisto, Jonas Abrahamsson, Sofie Johansson Alm, Kirsi Jahnukainen, Birgitte Lausen, Dirk Reinhardt, Bernward Zeller, Nils Von Neuhoff, Linda Fogelstrand, Henrik Hasle
Journal: Blood (2018)
Abstract 15557: African American Race and Hypertension Are Associated With Chemotherapy Related Cardiac Dysfunction in Patients With Breast Cancer
Authors: Thong Nguyen, Kavya Kannan, Jonathan Brock, Alexandra Thomas, Jennifer Jordan, William G Hundley, Diego Malaver, Sujethra Vasu
Journal: Circulation (2018)

Introduction: Anthracycline and trastuzumab chemotherapy related cardiac dysfunction (CTRCD) contributes to increased morbidity to breast cancer patients, yet predictors of CTRCD are not well defin...
AB0171 B cell subpopulations in lupus nephritispatients: correlations with disease onset and outcomes
Authors: V. Varriano, L. Petricca, B. Tolusso, S. Costanzi, G. Maria Rita, A. Paglionico, C. Di Mario, G. Tanti, G. Vischini, G. Gambaro, G. Ferraccioli, E. Gremese
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> the relationship between B cells subsets distribution, clinical and laboratory parameters, therapeutic response and prognosis in lupus nephritis (LN) is still underestimated. <h3>Objectives</h3> The aim of our study is to establish the value of B cells subsets as biomarkers in patients with active LN than controls, in patients at the onset of renal manifestation than patients with renal flare, and finally in nephritic patients in relation to their clinical and laboratory characteristics at the baseline and during the course of the disease. <h3>Methods</h3> 50 patients with a diagnosis of LN have been evaluated every tree months. Laboratory, immunological and disease activity data were collected at the baseline and at 6 (T6), 12 (T12), 24 (T24), 36 (T36) months and at the last follow-up (FU). Number of renal flares, time to renal remission and persistent proteinuria at the last FU were evaluated. B cell subsets were obtained through cytofluorimetry and classified using C27/IgD classification. The characterisation of B cells subsets was realised in 50 LN patients and 37 healthy controls. <h3>Results</h3> LN patients had a lower percentage of CD19 +cells than controls (9.2% vs 10.6%; p=0.01) as well as a lower percentage of memory unswitched cells CD27 +IgD+ (10.7% vs 15.3%; p&lt;0.001) while patients had an higher percentage of plasmablasts and double negative memory cells CD27-IgD- (respectively 5.9% vs 1%; p&lt;0.001% and 10.9% vs 4.1%; p=0.01). No significant differences regardless B cells subsets were found between early LN patients and long ones as well as between LN patients at the onset and LN patients during renal flare. We found a correlation between an higher disease activity (assessed with SLEDAI 2K) and lower percentage of memory B cells IgD-CD27+ (p=0.02). Double negative B cells CD27-IgD- tended to be correlated with an higher disease activity. Of interest the correlation between persistent proteinuria detected during the follow-up and a lower percentage of plasmablasts at the baseline (p=0.01). <h3>Conclusions</h3> The alteration of B cells subsets is an early event in LN without differences regardless the period of renal involvement (nephritic onset or later LN development). The association between persistent proteinuria and a lower percentage of plasmablasts at the baseline could be a negative prognostic factor considering the correlation between persistent proteinuria and worse renal outcome. <h3>Disclosure of Interest</h3> None declared
THU0515 Somatosensory temporal discrimination is impaired in fibromyalgia
Authors: Z. Gunendi, M. Polat, D. Vurallı, B. Cengiz
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Fibromyalgia is the prototypical central sensitivity syndrome which is associated with increased sensitivity to pain and other stimuli. Somatosensory temporal discrimination (STD) is the perception of two discrete stimuli applied at short intervals as separate. The evaluation of STD ability essentially provides information about central processing of sensory stimuli.<sup>1</sup> <h3>Objectives</h3> In this study, we aimed to evaluate whether STD ability, which requires an intact central sensory processing, is altered in patients with fibromyalgia. <h3>Methods</h3> Fifteen patients with fibromyalgia and 15 healthy subjects participated in the study. Demographic characteristics of participants and severity for fatigue, sleep quality, cognitive symptoms, somatic symptoms and health-related quality of life in fibromyalgia patients were recorded. STD thresholds were measured from the dorsum of the dominant hands of the participants by using a constant current stimulator.<sup>2</sup> <h3>Results</h3> Patients with fibromyalgia had higher STD thresholds than healthy subjects (table 1). There were significant correlations between STD thresholds and pain intensity, fibromyalgia impact questionnaire scores and symptom severity scale scores in fibromyalgia group (p=0.006, r=0.68; p=0.037, r=0.54; p=0.017, r=0.61 respectively). <b>Table 1 STDT measures and clinical characteristics of study participants</b> VAS: Visual analogue scale, FIQ: Fibromyalgia impact questionnaire, SSSS: Symptom severity scale score, STDT: Somatosensory temporal discrimination threshold, SD: Standard deviation, CI: Confidence interval <h3>Conclusions</h3> Somatosensory temporal discrimination ability is impaired in fibromyalgia patients compared to healthy subjects. Disrupted somatosensory temporal discrimination ability correlates with increased widespread pain and severity of other symptoms including fatigue, sleep quality, cognitive symptoms, somatic symptoms and decreased functional status. The impaired somatosensory temporal discrimination ability indicates an alteration in higher cognitive sensory processing in fibromyalgia. <h3>References</h3> [1] Vuralli D, Boran HE, Cengiz B, Coskun O, Bolay H. Somatosensory temporal discrimination remains intact in tension-type headache whereas it is disrupted in migraine attacks. Cephalalgia2017Nov;37(13):1241–1247. [2] Conte A, Modugno N, Lena F, Dispenza S, Gandolfi B, Iezzi E, Fabbrini G, Berardelli A. Subthalamic nucleus stimulation and somatosensory temporal discrimination in Parkinson's disease. Brain 2010 Sep;133(9):2656–63. <h3>Disclosure of Interest:</h3> None declared
P2X7 receptor restrains pathogenic Tfh cell generation in systemic lupus erythematosus
Authors: Caterina E. Faliti, Roberta Gualtierotti, Elsa Rottoli, Maria Gerosa, Lisa Perruzza, Andrea Romagnani, Giovanni Pellegrini, Benedetta De Ponte Conti, Riccardo L. Rossi, Marco Idzko, Emilia M.C. Mazza, Silvio Bicciato, Elisabetta Traggiai, Pier Luigi Meroni, Fabio Grassi
Journal: The Journal of Experimental Medicine (2019)

Altered control of T follicular helper (Tfh) cells can lead to generation of autoantibodies and autoimmune manifestations. Signaling pathways that selectively limit pathogenic responses without affecting the protective function of Tfh cells are unknown. Here we show that the ATP-gated ionotropic P2X7 receptor restricts the expansion of aberrant Tfh cells and the generation of self-reactive antibodies in experimental murine lupus, but its activity is dispensable for the expansion of antigen-specific Tfh cells during vaccination. P2X7 stimulation promotes caspase-mediated pyroptosis of Tfh cells and controls the development of pathogenic ICOS+ IFN-γ–secreting cells. Circulating Tfh cells from patients with systemic lupus erythematosus (SLE) but not primary antiphospholipid syndrome (PAPS), a nonlupus systemic autoimmune disease, were hyporesponsive to P2X7 stimulation and resistant to P2X7-mediated inhibition of cytokine-driven expansion. These data point to the P2X7 receptor as a checkpoint regulator of Tfh cells; thus, restoring P2X7 activity in SLE patients could selectively limit the progressive amplification of pathogenic autoantibodies, which deteriorate patients’ conditions.